Opioid Rapid Response System: Naloxone Training in Communities

Status Recruiting

Clinical Trial Summary

The pervasive impact of the opioid epidemic has touched all layers of society for the past two decades, resulting in over 115 deaths daily and imposing annual costs of $78.5 billion. Responding swiftly to overdoses, akin to various medical emergencies, poses a significant challenge, particularly in geographically dispersed rural areas and densely populated urban settings. Effectively delivering the life-saving drug naloxone, which counteracts the effects of overdoses, necessitates a well-coordinated and cost-efficient response system. Simply opting for widespread distribution of naloxone, even with citizen involvement, proves to be a financially burdensome approach when compared to more targeted strategies. Moreover, obstacles such as limited access, inadequate or unavailable naloxone training, and delayed response times from emergency responders compound the problem. Addressing these issues, the proposed Opioid Rapid Response System (ORRS) project seeks to advance prevention science by adopting an innovative approach that incorporates technology and contemporary communication theory. The primary objective of the ORRS project is to mitigate opioid overdose deaths by enlisting and training citizens to administer naloxone in response to such events. Leveraging the PulsePoint health app, which connects citizens to cardiac events, the ORRS project will extend its capabilities to respond to overdose incidents. This initiative involves comprehensive development of ORRS, followed by a randomized clinical trial on a national scale to assess its effectiveness. The study aims to contribute to both prevention and implementation science by identifying optimal recruitment strategies and testing a model of online training. In pursuit of these objectives, the study is guided by the following Specific Aims: SA 1: Refine and complete the development of ORRS. SA 2: Conduct a randomized clinical trial to evaluate the effectiveness of the intervention. SA 3: Prepare ORRS for dissemination.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06238128
Study type	Interventional
Source	University of Missouri-Columbia
Contact	Hye Jeong Choi
Phone	5738844592
Email	choihyej@health.missouri.edu
Status	Recruiting
Phase	N/A
Start date	May 24, 2024
Completion date	July 31, 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04372238` - The Rhode Island Prescription and Illicit Drug Study	N/A
Recruiting	`NCT03924505` - Preventing Opioid Overdose Mortality in the United States	N/A
Completed	`NCT05093309` - Preventing Opioid Overdose Deaths by Empowering Pharmacists to Dispense Naloxone	N/A
Completed	`NCT05219669` - Pharmacokinetic Evaluation of Intranasal Nalmefene Using Three Dosing Regimens	Phase 1
Completed	`NCT04317053` - Multi-Center Randomized Controlled Trial of Relay- NYC's Nonfatal Overdose Response Program	Phase 3
Not yet recruiting	`NCT06466005` - UnityPhilly Response App for Overdose Reversal
Recruiting	`NCT04815590` - Extended-release Injectable Buprenorphine for Individuals at High Risk of Overdose
Active, not recruiting	`NCT05096429` - Preventing Overdose Using Information and Data From the Environment	N/A
Suspended	`NCT05114460` - Vaped Marijuana to Attenuate Naloxone-Precipitated Withdrawal	Phase 2
Completed	`NCT02662153` - Incidence and Predictors of Opioid Overdose and Death Among Long-Term Users of Opioid Analgesics
Active, not recruiting	`NCT05944133` - Health Insurance Instability and Mortality Among Patients Receiving Bup Tx for OUD
Completed	`NCT05377255` - Pharmacokinetics (PK) and Safety of Multiple Doses of Intranasal Naloxone in Healthy Adults	Phase 1
Recruiting	`NCT05877118` - Improving Availability of Intranasal Naloxone	N/A
Recruiting	`NCT05072249` - European Cohort Study of the Effectiveness of Take Home Naloxone
Withdrawn	`NCT05808881` - Clinical Outcomes From Nalmefene	Phase 4
Not yet recruiting	`NCT01622504` - Naloxone Nasal Spray Pharmacokinetic Study	Phase 1
Not yet recruiting	`NCT06429436` - Vending Machine Naloxone Distribution for Your Community (VENDY)	Phase 4
Completed	`NCT05506267` - Development of a Tracheal Sound Sensor
Completed	`NCT02535494` - Risks and Benefits of Naloxone Prescribing	N/A
Not yet recruiting	`NCT06408714` - Nalmefene vs Naloxone for the Treatment of Recurrent Respiratory Depression After Opioid Overdose	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.